Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Northwestern scientists identify key genes behind Parkinson's development

Northwestern scientists identify key genes behind Parkinson's development

Heavy drinking linked to increased risk of brain lesions

Heavy drinking linked to increased risk of brain lesions

Study explores impact of parental Alzheimer’s on tau protein spread in the brain

Study explores impact of parental Alzheimer’s on tau protein spread in the brain

Tim-3 identified as promising therapeutic target for Alzheimer's disease

Tim-3 identified as promising therapeutic target for Alzheimer's disease

Neural organoids offer insight into mechanisms of dementia

Neural organoids offer insight into mechanisms of dementia

Breakthrough nanoparticle delivery method targets brain inflammation for multiple conditions

Breakthrough nanoparticle delivery method targets brain inflammation for multiple conditions

Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment

Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment

Novel computational tool helps scientists detect hidden cell types behind disease

Novel computational tool helps scientists detect hidden cell types behind disease

Immigration crackdowns disrupt the caregiving industry. Families pay the price.

Immigration crackdowns disrupt the caregiving industry. Families pay the price.

NUZ-001 shows positive results in human 3D brain model

NUZ-001 shows positive results in human 3D brain model

Neuropathological basis of visual dysfunction in rare Alzheimer's forms

Neuropathological basis of visual dysfunction in rare Alzheimer's forms

New drug shows neuroprotective and anti-inflammatory effects in murine models of Alzheimer's

New drug shows neuroprotective and anti-inflammatory effects in murine models of Alzheimer's

Senolytics offer hope for more precise Alzheimer's treatments

Senolytics offer hope for more precise Alzheimer's treatments

Study links low LDL-C levels to reduced risk of dementia

Study links low LDL-C levels to reduced risk of dementia

Weight training shields the brain from dementia in older adults

Weight training shields the brain from dementia in older adults

Virtual reality offers new approach for early Alzheimer's detection

Virtual reality offers new approach for early Alzheimer's detection

A new blood test could improve how Alzheimer’s disease is diagnosed

A new blood test could improve how Alzheimer’s disease is diagnosed

Mayo Clinic launches study to investigate rapidly progressive dementia in Alzheimer's

Mayo Clinic launches study to investigate rapidly progressive dementia in Alzheimer's

Study helps characterize how sleep deficiency may relate to Alzheimer's pathogenesis

Study helps characterize how sleep deficiency may relate to Alzheimer's pathogenesis

Blood test offers insight into Alzheimer's stage and severity

Blood test offers insight into Alzheimer's stage and severity

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.